KilgourMD Releases Phase II Clinical Trial Data on Menopausal Hair Loss

KilgourMD has released results from an independent, four-month phase II clinical trial evaluating the KilgourMD System, composed of prevention and treatment serums, in 43 menopausal-aged women experiencing androgenetic alopecia.

Overall, the study found clinically meaningful regrowth in record time, alongside validated reductions in hair shedding.

By day 120, results showed that 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a threshold dermatologists consider a meaningful visual change, while 26% showed a full one grade improvement, according to the company. Across the full study population, participants experienced an average 11.1% improvement in Ludwig score within just four months.

In addition, there was a dramatic reduction in hair shedding, according to the brand. Standardized combing and washing assessments further revealed a 60% reduction in hair shedding by month four, indicating rapid normalization of the hair growth cycle and improved follicular health. These reductions were observed as early as day 45, when greater than 95% of the trial participants demonstrated a decrease from baseline in terminal hair shedding count, as measured by standardized hair washing studies in the lab.

Regrowth outcomes were graded by two independent board-certified dermatologists, with high-resolution imaging confirming visible improvements in hair density and scalp coverage over time. Simultaneously, consumer-reported outcomes reinforced the clinical findings: more than 80% of participants reported noticeable improvements in hair density, health, and overall appearance by the end of the study.

According to the company, unlike prior studies in the category, eligibility required a clinically significant level of hair loss, ensuring results reflected true therapeutic impact, and the outcome measures were objective and dermatologist-evaluated, rather than the consumer perception studies typically used by cosmetic brands.

“Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning. This study validates not only the performance of the KilgourMD System, but also the importance of designing and testing solutions specifically for this population. These results represent a meaningful step forward in how menopausal hair loss is treated,” Dr. James Kilgour, board-certified dermatologist, founder and CEO, said in a statement.